Search Results - "Verbaan, H."

Clinical trial: colectomy after rescue therapy in ulcerative colitis – 3‐year follow‐up of the Swedish‐Danish controlled infliximab study by Gustavsson, A., Järnerot, G., Hertervig, E., Friis‐Liby, I., Blomquist, L., Karlén, P., Grännö, C., Vilien, M., Ström, M., Verbaan, H., Hellström, P. M., Magnuson, A., Halfvarson, J., Tysk, C.

“…Aliment Pharmacol Ther 2010; 32: 984–989 Summary Background  The long‐term efficacy of infliximab as rescue therapy in steroid‐refractory ulcerative colitis is…”
Get full text

Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis by Danielsson Borssén, Åsa, Marschall, Hanns-Ulrich, Bergquist, Annika, Rorsman, Fredrik, Weiland, Ola, Kechagias, Stergios, Nyhlin, Nils, Verbaan, Hans, Nilsson, Emma, Werner, Mårten

“…Background: Epidemiological studies of autoimmune hepatitis (AIH) show varying figures on prevalence and incidence, and data on the long-term prognosis are…”
Get full text

Histological improvement of liver fibrosis in well-treated patients with autoimmune hepatitis: A cohort study by Borssén, Åsa D., Palmqvist, Richard, Kechagias, Stergios, Marschall, Hanns-Ulrich, Bergquist, Annika, Rorsman, Fredrik, Weiland, Ola, Verbaan, Hans, Nyhlin, Nils, Nilsson, Emma, Werner, Mårten

“…Autoimmune hepatitis (AIH) is a chronic autoimmune liver disease that if left untreated may lead to the development of cirrhosis. Previous studies on AIH…”
Get full text

Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation by Ackefors, Malin, Castedal, Maria, Dahlgard, Olav, Verbaan, Hans, Gjertsen, Henrik, Wernerson, Annika, Weiland, Ola

“…Abstract Background: Relapse of hepatitis C virus (HCV) infection after liver transplantation (LT) is universal. Tolerance for treatment with…”
Get full text

Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg‐interferon α‐2b and ribavirin by MANGIA, A., DALGARD, O., MINERVA, N., VERBAAN, H., BACCA, D., RING‐LARSEN, H., COPETTI, M., CARRETTA, V., PIAZZOLLA, V., COZZOLONGO, R., MOTTOLA, L., ANDRIULLI, A.

“…Aliment Pharmacol Ther 31, 1346–1353 Summary Background  The optimal dose of ribavirin to be used in combination with Peg‐IFN in patients with HCV genotypes 2…”
Get full text

412 THE USEFULNESS OF DEFINING RVR BY A VERY SENSITIVE ASSAY DURING THE TREATMENT OF HCV GENOTYPE 3 INFECTION; A COMPARISON OF TMA AND AMPLICOR by Dalgard, O, Martinot-Peignoux, M, Holberg-Petersen, M, Skaug, K, Verbaan, H, Ring-Larsen, H, Bjøro, K, Marcellin, P

Get full text

1151 GENETIC VARIANTS AT ITPA THE LOCUS PROTECTS AGAINST RIBAVIRIN-INDUCED HEMOLYTIC ANEMIA – A REPLICATION STUDY IN A SCANDINAVIAN HCV G2/G3 COHORT by Eskesen, A, Melum, E, Moghaddam, A, Bjøro, K, Verbaan, H, Ring-Larsen, H, Dalgard, O

Get full text

Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin by Mangia, A, Dalgard, O, Minerva, N, Verbaan, H, Bacca, D, Ring-Larsen, H, Copetti, M, Carretta, V, Piazzolla, V, Cozzolongo, R, Mottola, L, Andriulli, A

“…The optimal dose of ribavirin to be used in combination with Peg-IFN in patients with HCV genotypes 2 and 3 undergoing short treatment has not been…”
Get full text

The clinical importance in differentiating portal from mesenteric venous thrombosis by Acosta, S, Alhadad, A, Verbaan, H, Ogren, M

“…To relate the extent of portomesenteric thrombosis to the risk of intestinal infarction, concomitant venous thromboembolism and underlying diseases…”
Get more information

728 IS SUSTAINED VIROLOGICAL RESPONSE TO HCV TREATMENT ASSOCIATED WITH A CLINICAL IMPORTANT IMPROVEMENT IN VITALITY? by Dalgard, O, BjOro, K, Ring-Larsen, H, Verbaan, H

Get full text

Extrahepatic manifestations of chronic hepatitis C infection and the interrelationship between primary Sjögren's syndrome and hepatitis C in Swedish patients by Verbaan, H., Carlson, J., Eriksson, S., Larsson, Å., Liedholm, R., Manthorpe, R., Tabery, H., Widell, A., Lindgren, S.

“…Objective. To analyse the frequency of some extrahepatic manifestations of chronic hepatitis C virus (HCV) infection in northern European patients, including a…”
Get full text

[128] PEGINTERFERON o-2b AND RIBAVIRIN FOR 14 OR 24 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 AND RAPID VIROLOGICAL RESPONSE. THE NORTH-C TRIAL by Dalgard, O, Bjoro, K, Ring-Larsen, H, Verbaan, H

Get full text

PIN37 The Cost of Managing Chronic Hepatitis C in Sweden - Medical Resource Utilisation in Different Stages of the Disease by Orrskog, S, Friberg, S, Lenre, M, Bäckman, L, Duberg, A.S, Flamholc, L, Friman, S, Hollander, A, Sangfelt, P, Verbaan, H, Oksanen, A

Get full text

630 RIBAVIRIN (RBV) DOSAGE AS INDEPENDENT PREDICTOR OF RVR IN HCV GENOTYPE 2 (HCV-2) AND 3 (HCV-3) PATIENTS UNDERGOING COMBINED TREATMENT WITH PEG INTERFERON (PEG-IFN) ALPHA-2B by Mangia, A, Dalgard, O, Minerva, N, Verbaan, H, Scotto, G, Bacca, D, Agostinacchio, E, Bjoro, K, Carretta, V, Piazzolla, V, Cozzolongo, R, Romano, M, Mottola, L, Andriulli, A

Get full text

Prevalence and Clinical Spectrum of Chronic Viral Hepatitis in a Middle-aged Swedish General Urban Population by HOFFMANN, G, BERGLUND, G, ELMSTAHL, S, ERIKSSON, S, VERBAAN, H, WIDELL, A, LINDGREN, S

“…Background: Although abundant data are available regarding the prevalence of chronic hepatitis B or C virus (HBV, HCV) among both blood donors and patients…”
Get full text

A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C—Associated Liver Cirrhosis by Aleman, Soo, Rahbin, Nogol, Weiland, Ola, Davidsdottir, Loa, Hedenstierna, Magnus, Rose, Nina, Verbaan, Hans, Stål, Per, Carlsson, Tony, Norrgren, Hans, Ekbom, Anders, Granath, Fredrik, Hultcrantz, Rolf

“…Background. The long-term effect of sustained virologic response (SVR) to antiviral therapy on the risk of developing hepatocellular carcinoma (HCC), liver…”
Get full text

Intravenous drug abuse--the major route of hepatitis C virus transmission among alcohol-dependent individuals? by Verbaan, H, Andersson, K, Eriksson, S

“…As the prevalence of hepatitis C virus (HCV) antibodies has been reported to be high among alcohol-dependent individuals, we screened prospectively 310…”
Get more information

Factors associated with cirrhosis development in chronic hepatitis C patients from an area of low prevalence by Verbaan, H., Widell, A., Bondeson, L., Andersson, K., Eriksson, S.

“…The aim of this study was to evaluate the importance of different endogenous and exogenous factors associated with cirrhosis development among heptatitis C…”
Get full text

Non-Invasive Assessment of Inflammatory Activity and Fibrosis (Grade and Stage) in Chronic Hepatitis C Infection by Verbaan, H., Bondeson, L., Eriksson, S.

“…Background: Much effort has been expended in finding non-invasive alternatives to percutaneous liver biopsy for assessing the histological extent of liver…”
Get full text

Long-Term Outcome of Chronic Hepatitis C Infection in a Low-Prevalence Area by VERBAAN, H, HOFFMANN, G, LINDGREN, S, NILSSON, S, WIDELL, A, ERIKSSON, S

“…Background: Although hepatitis C virus (HCV) infection is recognized as an important causative factor in the development of liver cirrhosis and hepatocellular…”
Get full text